CRNX
Price
$52.99
Change
-$2.38 (-4.30%)
Updated
Dec 18, 04:10 PM (EDT)
90 days until earnings call
ZVRA
Price
$8.28
Change
-$0.21 (-2.48%)
Updated
Dec 18, 04:37 PM (EDT)
72 days until earnings call
Ad is loading...

CRNX vs ZVRA

Header iconCRNX vs ZVRA Comparison
Open Charts CRNX vs ZVRABanner chart's image
Crinetics Pharmaceuticals
Price$52.99
Change-$2.38 (-4.30%)
Volume$800
CapitalizationN/A
Zevra Therapeutics
Price$8.28
Change-$0.21 (-2.48%)
Volume$1K
CapitalizationN/A
CRNX vs ZVRA Comparison Chart
Loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRNX vs. ZVRA commentary
Dec 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a Buy and ZVRA is a Hold.

COMPARISON
Comparison
Dec 18, 2024
Stock price -- (CRNX: $55.37 vs. ZVRA: $8.48)
Brand notoriety: CRNX and ZVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 154% vs. ZVRA: 78%
Market capitalization -- CRNX: $5.13B vs. ZVRA: $452.63M
CRNX [@Biotechnology] is valued at $5.13B. ZVRA’s [@Biotechnology] market capitalization is $452.63M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 1 FA rating(s) are green whileZVRA’s FA Score has 1 green FA rating(s).

  • CRNX’s FA Score: 1 green, 4 red.
  • ZVRA’s FA Score: 1 green, 4 red.
According to our system of comparison, both CRNX and ZVRA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 4 TA indicator(s) are bullish while ZVRA’s TA Score has 3 bullish TA indicator(s).

  • CRNX’s TA Score: 4 bullish, 6 bearish.
  • ZVRA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both CRNX and ZVRA are a bad buy in the short-term.

Price Growth

CRNX (@Biotechnology) experienced а -3.15% price change this week, while ZVRA (@Biotechnology) price change was -4.72% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.65%. For the same industry, the average monthly price growth was +1.45%, and the average quarterly price growth was +4.23%.

Reported Earning Dates

CRNX is expected to report earnings on Mar 18, 2025.

ZVRA is expected to report earnings on Feb 28, 2025.

Industries' Descriptions

@Biotechnology (-3.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($5.14B) has a higher market cap than ZVRA($453M). CRNX YTD gains are higher at: 55.621 vs. ZVRA (29.466). ZVRA has higher annual earnings (EBITDA): -78.22M vs. CRNX (-304.51M). CRNX has more cash in the bank: 863M vs. ZVRA (89.4M). CRNX has less debt than ZVRA: CRNX (52.5M) vs ZVRA (59.9M). ZVRA has higher revenues than CRNX: ZVRA (24.5M) vs CRNX (1.04M).
CRNXZVRACRNX / ZVRA
Capitalization5.14B453M1,134%
EBITDA-304.51M-78.22M389%
Gain YTD55.62129.466189%
P/E RatioN/AN/A-
Revenue1.04M24.5M4%
Total Cash863M89.4M965%
Total Debt52.5M59.9M88%
FUNDAMENTALS RATINGS
CRNX vs ZVRA: Fundamental Ratings
CRNX
ZVRA
OUTLOOK RATING
1..100
1865
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
83
Overvalued
PROFIT vs RISK RATING
1..100
995
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
4438
P/E GROWTH RATING
1..100
10028
SEASONALITY SCORE
1..100
3n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZVRA's Valuation (83) in the null industry is in the same range as CRNX (92) in the Pharmaceuticals Major industry. This means that ZVRA’s stock grew similarly to CRNX’s over the last 12 months.

CRNX's Profit vs Risk Rating (9) in the Pharmaceuticals Major industry is significantly better than the same rating for ZVRA (95) in the null industry. This means that CRNX’s stock grew significantly faster than ZVRA’s over the last 12 months.

CRNX's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as ZVRA (98) in the null industry. This means that CRNX’s stock grew similarly to ZVRA’s over the last 12 months.

ZVRA's Price Growth Rating (38) in the null industry is in the same range as CRNX (44) in the Pharmaceuticals Major industry. This means that ZVRA’s stock grew similarly to CRNX’s over the last 12 months.

ZVRA's P/E Growth Rating (28) in the null industry is significantly better than the same rating for CRNX (100) in the Pharmaceuticals Major industry. This means that ZVRA’s stock grew significantly faster than CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXZVRA
RSI
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
N/A
Declines
ODDS (%)
Bearish Trend 6 days ago
80%
Bearish Trend 7 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Ad is loading...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
OCEN21.28N/A
N/A
NYLI Clean Oceans ETF
PLTM9.08N/A
-0.05%
GraniteShares Platinum Trust
PYLD26.11-0.02
-0.08%
PIMCO Multisector Bond Active ETF
IGOV39.45-0.11
-0.28%
iShares International Treasury Bond ETF
FVC38.04-0.36
-0.94%
First Trust Dorsey Wright Dynamic Foc 5

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XENE. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
+1.35%
XENE - CRNX
47%
Loosely correlated
-0.07%
ARWR - CRNX
47%
Loosely correlated
-0.45%
PGEN - CRNX
44%
Loosely correlated
+2.46%
RARE - CRNX
44%
Loosely correlated
-0.99%
ELVN - CRNX
44%
Loosely correlated
+3.48%
More

ZVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZVRA has been loosely correlated with AXON. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if ZVRA jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZVRA
1D Price
Change %
ZVRA100%
+0.47%
AXON - ZVRA
33%
Loosely correlated
-2.09%
GOSS - ZVRA
33%
Poorly correlated
+1.71%
VCYT - ZVRA
33%
Poorly correlated
-2.52%
PGEN - ZVRA
32%
Poorly correlated
+2.46%
CRNX - ZVRA
31%
Poorly correlated
+1.35%
More